Biopharma’s COVID Capital Comeback
Biopharma’s COVID Capital Comeback What a difference a few months can make – especially during a pandemic. Heading into 2020, […]
Capital Markets
Capital Markets
Capital Markets, Capital Raising, Market Trends
Biopharma’s COVID Capital Comeback – A Whitepaper
Heading into 2020, biopharma looked like it would be typecast in its typical election year role: the big business scapegoat for everything that’s wrong in health care. There had been the usual big Phase 3 trial failures.
Capital Markets, News
Panel Recording: The Unexpected IPO Boom in Biopharma in Q2
CATEGORIES News Events Publications ARCHIVE Panel Recording: The Unexpected IPO Boom in Biopharma in Q2 Locust Walk partnered with Applied